WO2000039301A3 - Methods for using mycobacterium tuberculosis molecules as immunological adjuvants - Google Patents
Methods for using mycobacterium tuberculosis molecules as immunological adjuvants Download PDFInfo
- Publication number
- WO2000039301A3 WO2000039301A3 PCT/US1999/030975 US9930975W WO0039301A3 WO 2000039301 A3 WO2000039301 A3 WO 2000039301A3 US 9930975 W US9930975 W US 9930975W WO 0039301 A3 WO0039301 A3 WO 0039301A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mycobacterium tuberculosis
- methods
- immunological adjuvants
- proteins
- antigen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU25945/00A AU2594500A (en) | 1998-12-24 | 1999-12-21 | Methods for using mycobacterium tuberculosis molecules as immunological adjuvants |
EP99968552A EP1141312A2 (en) | 1998-12-24 | 1999-12-23 | Methods for using mycobacterium tuberculosis molecules as immunological adjuvants |
CA002356669A CA2356669A1 (en) | 1998-12-24 | 1999-12-23 | Methods for using mycobacterium tuberculosis molecules as immunological adjuvants |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22041698A | 1998-12-24 | 1998-12-24 | |
US09/220,416 | 1998-12-24 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2000039301A2 WO2000039301A2 (en) | 2000-07-06 |
WO2000039301A3 true WO2000039301A3 (en) | 2001-05-03 |
WO2000039301A9 WO2000039301A9 (en) | 2001-10-18 |
Family
ID=22823460
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/030975 WO2000039301A2 (en) | 1998-12-24 | 1999-12-23 | Methods for using mycobacterium tuberculosis molecules as immunological adjuvants |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1141312A2 (en) |
AU (1) | AU2594500A (en) |
CA (1) | CA2356669A1 (en) |
WO (1) | WO2000039301A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0003082D0 (en) * | 2000-02-10 | 2000-03-29 | Glaxo Group Ltd | Vaccine |
AU2001271963A1 (en) * | 2000-07-10 | 2002-01-21 | Colorado State University Research Foundation | Mid-life vaccine and methods for boosting anti-mycobacterial immunity |
NZ519667A (en) * | 2002-06-19 | 2005-02-25 | Univ Massey | A putative 23kDa lipoprotein from Mycobacterium paratuberculosis and its use in Johne's disease |
DE60325586D1 (en) * | 2003-08-22 | 2009-02-12 | Axenoll Ag | Mycobacterial protein antigens for cancer therapy and vaccination |
NZ581306A (en) | 2004-11-16 | 2011-03-31 | Crucell Holland Bv | Multivalent vaccines comprising recombinant viral vectors |
EP2368568A1 (en) * | 2006-11-01 | 2011-09-28 | Immport Therapeutics, INC. | Compositions and methods for immunodominant antigens |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5599545A (en) * | 1990-05-07 | 1997-02-04 | University College London | Mycobacterium as adjuvant for antigens |
WO1997009428A2 (en) * | 1995-09-01 | 1997-03-13 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
WO1998016646A2 (en) * | 1996-10-11 | 1998-04-23 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
WO1998044119A1 (en) * | 1997-04-02 | 1998-10-08 | Statens Serum Institut | NUCLEIC ACID FRAGMENTS AND POLYPEPTIDE FRAGMENTS DERIVED FROM $i(M. TUBERCULOSIS) |
-
1999
- 1999-12-21 AU AU25945/00A patent/AU2594500A/en not_active Abandoned
- 1999-12-23 EP EP99968552A patent/EP1141312A2/en not_active Withdrawn
- 1999-12-23 WO PCT/US1999/030975 patent/WO2000039301A2/en not_active Application Discontinuation
- 1999-12-23 CA CA002356669A patent/CA2356669A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5599545A (en) * | 1990-05-07 | 1997-02-04 | University College London | Mycobacterium as adjuvant for antigens |
WO1997009428A2 (en) * | 1995-09-01 | 1997-03-13 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
WO1998016646A2 (en) * | 1996-10-11 | 1998-04-23 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
WO1998044119A1 (en) * | 1997-04-02 | 1998-10-08 | Statens Serum Institut | NUCLEIC ACID FRAGMENTS AND POLYPEPTIDE FRAGMENTS DERIVED FROM $i(M. TUBERCULOSIS) |
Non-Patent Citations (3)
Title |
---|
LAUNOIS P ET AL: "T-CELL-EPITOPE MAPPING OF THE MAJOR SECRETED MYCOBACTERIAL ANTIGEN AG85A IN TUBERCULOSIS AND LEPROSY", INFECTION AND IMMUNITY,US,AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, vol. 62, no. 9, 1 September 1994 (1994-09-01), pages 3679 - 3687, XP000572211, ISSN: 0019-9567 * |
SINHA R K ET AL: "Immunobiological properties of a 30 kDa secretory protein of Mycobacterium tuberculosis H37Ra", VACCINE,GB,BUTTERWORTH SCIENTIFIC. GUILDFORD, vol. 15, no. 6-7, 1 April 1997 (1997-04-01), pages 689 - 699, XP004064532, ISSN: 0264-410X * |
SKEIKY ET AL: "LeIF: a recombinant Leishmania protein that induces and IL-12-mediated Th cytokine profile", JOURNAL OF IMMUNOLOGY,US,THE WILLIAMS AND WILKINS CO. BALTIMORE, 1998, pages 6171 - 6179, XP002103156, ISSN: 0022-1767 * |
Also Published As
Publication number | Publication date |
---|---|
AU2594500A (en) | 2000-07-31 |
CA2356669A1 (en) | 2000-07-06 |
WO2000039301A9 (en) | 2001-10-18 |
EP1141312A2 (en) | 2001-10-10 |
WO2000039301A2 (en) | 2000-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2311952A3 (en) | Antibodies to MRT-1 protein or fragments thereof | |
WO1995029193A3 (en) | Melanoma antigens | |
GB2303854B (en) | Helicobacter proteins and vaccines | |
EP1092774A3 (en) | Borrelia burgdorferi antigen OspA, gene encoding it and uses thereof | |
PL325373A1 (en) | Compounds and methods useful in tuberculosos immunotherapy and diagnostics | |
CA2190473A1 (en) | Recombinant papilloma virus l1 | |
EP1847549A3 (en) | Papillomavirus polyprotein constructs | |
NZ508366A (en) | Neisseria meningitidis antigens and compositions | |
WO2000039299A3 (en) | Streptococcus antigens | |
WO2000006737A8 (en) | Streptococcus pneumoniae proteins and nucleic acid molecules | |
BG102983A (en) | Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application | |
NZ335485A (en) | Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof | |
WO2002005146A3 (en) | Method for disigning protein libraries with altered immunogenicity | |
WO2003068941A3 (en) | Modulation of immune response by non-peptide binding stress response polypeptides | |
WO1998016646A3 (en) | Compounds and methods for immunotherapy and diagnosis of tuberculosis | |
WO1999042588A3 (en) | Group b streptococcus antigens | |
IL111479A0 (en) | Chimeric proteins comprising borrelia polypetides and uses therefor | |
WO2000006736A3 (en) | Nucleic acids and proteins from group b streptococcus | |
WO1996021734A3 (en) | P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods | |
WO2000012535A3 (en) | Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof | |
WO2000039301A3 (en) | Methods for using mycobacterium tuberculosis molecules as immunological adjuvants | |
EP0972054A4 (en) | Enhancement of immune response using targeting molecules | |
WO2000063385A3 (en) | Nucleic acid immunization | |
NO20005952D0 (en) | Neisseria Meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies | |
CA2197651A1 (en) | Or-1 on orphan receptor belonging to the nuclear receptor family |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 2356669 Country of ref document: CA Ref country code: CA Ref document number: 2356669 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999968552 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999968552 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/7-7/7, DRAWINGS, REPLACED BY NEW PAGES 1/11-11/11; DUE TO LATE TRANSMITTAL BY THE RECEIVINGOFFICE |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999968552 Country of ref document: EP |